Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
Complete title: A Phase I Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Escalating Doses of Inotuzumab Ozogamicin (DA-EPOCH-InO) in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Research Study Description
This phase I trial studies the best dose of inotuzumab ozogamicin in combination with chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has come back (recurrent) or that does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin in combination with chemotherapy may kill more cancer cells than with chemotherapy alone in treating patients with recurrent or refractory B-cell acute lymphoblastic leukemia.
Eligibility Criteria (must meet the following to participate in this
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
|Seattle Cancer Care Alliance Intake Office
|800-804-8824 / 206-606-1024
Lymphoma, Non-Hodgkin (NHL); Lymphoma, Lymphoblastic (LBL)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.